Okay. Thank you very much. Thanks. So we are in an interesting market. So, that's what we do. So we actually automate what pathologists are doing. So we are, uh, supporting the diagnostic. So we perform quantitative analysis on those tissue samples processed in that process, enabling analysis to determine whether there is cancer present or not. And how serious is that, and what type of treatment is needed? So the market is interesting. We are dealing with very small sample sizes that contain a huge amount of data. So we are dealing with the size of the files. And, uh, it's really important that. So, you captured the information from those slides really precisely, carefully, and efficiently. So, that's what we do. So, as I said, there is a market. So there is an active problem recognition because there are about 100,000 pathologists in the world. There are about 3 billion glass slides diagnosed every year, typically using the traditional process with a microscope, now transitioning to digital and leveraging AI to automate the process. So the demand is there because the number of pathologies is not going up. Cancer cases are increasing, and the need for diagnosis is really on the rise. And there's a growing gap between those two things. And now we have proven that. We have the technology, we have good references, and we can help sort out those issues. And that's the business where we are at. So, we are really focusing on capturing the clinical opportunity, ensuring that they can handle the large workflows they have, and we can also open up new opportunities to leverage the digital information. As an example, the product that we developed together with Mayo Clinic, the CRC, enables you to take it to the next level. So you leverage the AI and quantitative analysis. Predictive models enhance patient outcome prediction and improve treatment decisions, showcasing the opportunities AI opens up. And of course in research in pharma. So we are still strong. And we want to make sure that we keep those good customers and sell models to those customers because they also have a need when it comes to new truck developments. So, extensive studies need to be conducted beforehand. So we have tools for that. We have the tools to build AI models and streamline drug development, allowing us to bring products to market faster. So we have a good offering in place. But obviously, moving forward into the coming years, we need to grow. And we've put a lot of effort into that. We have captured some nice opportunities now. So we need to make sure that we deliver on those exceedingly well. We will upsell those customers because we have sold them five AI models, but they will probably need 20 or 30 more going forward. So, considering all of these bigger customers that we have, we need to ensure they stay and they grow. And then, we need to acquire additional, similar types of customers over the next 2 or 3 years. Then the market will start scaling in volume.
There's regulation in place. There are references in place. There's a kind of blueprint for other hospitals on how to implement these solutions. They can be confident, given that leading organizations like Mayo Clinic, Paris Hospital Region, Veneto Region Health Authority, Fimlab Laboratories, or any of these players, are using it. Then other kinds of organizations can be confident as well, leveraging the benefits and starting to use the solution. The prerequisites are there.
The need is present, and so are the solutions. And we just need to make sure that we can scale and maintain confidence by ensuring our products are best in class and reliable. Because, of course, we are dealing with very critical matters. So we cannot afford mistakes, as you know. When we implemented the cardiovascular disease (CVD) solution, for example,
it was tested against human pathologists, ensuring that the AI performed at least at the same level as humans. Subsequently, it received the necessary approvals, thus improving the efficiency of pathologists in this field. But really, there's a lot of focus on growth in the coming years, ensuring that our product offerings remain competitive. At the moment, we have significant advantages over key competitors. Currently, most of the competition relies on so-called heatmaps to indicate whether a sample is cancerous or not, requiring pathologists to focus traditionally.
As you know, we delve a little deeper. We conduct quantitative analyses. We build the tools at a pixel level, allowing us to capture even the smallest piece of information from the slides. Then we conduct quantitative analyses again. We perform calculations on different cells and so forth. So we provide all the necessary information for diagnoses in a pre-prepared report. And that's also an extremely important aspect. First, you see the slide, then you receive the report with all the calculations. The pathologist then verifies the results. Further, it leads to a treatment decision by the physician responsible for making such decisions.
It is truly an automation tool, but also serves as a gateway to capabilities beyond human reach. We indeed have a fantastic team in place, forming a strong technical team. Moreover, we have a very strong science team and an equally capable sales team. Ensuring our small team comprises top talent and performs well is crucial, and currently, we are very pleased with our staff. They have been delivering the best solutions globally.
We have also been successful in introducing these solutions to the market. In this way, these are our focus areas moving forward. Considering our business targets for the mid to long term. We aim to be involved on the clinical side, ensuring we provide automation. This means delivering AI tools – not just the algorithms, but also all the necessary APIs and tools required for integration into hospital systems, enabling collaboration with other required systems, positioning us as a reliable software company that delivers, maintains, and develops its products.
That's the business we are engaged in. By 2027, we should achieve our first profitable year, as currently, it's a phase of investment. This is a venture into new business territory, establishing a solution, and opening up the market. We have been doing this successfully. By 2027, we anticipate being on a remarkable number.
This presents a massive opportunity. Achieving over one hundred million in sales should be our target for this decade. Furthermore, we can leverage this technology in several other fields because ultimately, when we consider AI for our technology company, we possess an incredible platform capable of diagnosing vast image files, targeting incredibly minute details. We could explore various solutions in this realm.
For instance, consider Force Medica from the US market. This was one of the significant deals in the first half of the year. Specifically, in the field of veterinary pathology, they are developing their own device and a comprehensive end-to-end solution for that market. And we are providing the technology for them so that, when they start mass production of their devices, they are equipped. Aiforia Technologies' initial purchase was primarily to acquire the development platform. But going forward, it's an opportunity to grow that alongside their sales as well. Of course, we need to secure those big accounts and ensure they are satisfied and using our services. That is what we are aiming to achieve. Short term, this year. With only about four or five months left in this year, but still time to make progress. Looking towards next year. We will introduce these AI models to the market. As you all know. There was a regulation change two years ago from the CVD standpoint. We've been addressing these issues and will soon introduce new models to the market. I think the solutions are ready, but getting the necessary regulatory approvals is the next step. Then we can make the announcements. Progress is being made. And, of course, focusing on partnerships. I believe this is a critical aspect. We collaborate with major cloud providers like Google and Amazon, which is significant. Providing the platform and technology behind it. We also work with scanner manufacturers, image management companies, and picture archiving solution providers.
We partner with all of these entities. In most cases, this collaboration stems from successful customer engagements. We implement these systems first, but notable sectors such as the Mayo Clinic are now in the Castile and León Region in Spain. This is advancing nicely. There are several similar companies with which we collaborate in this area, sometimes even with competitors, as they possess capabilities we might lack. And we certainly offer assets they don't have. Thus, we also collaborate with them. Then, achieving these key accounts, where the potential revenue is over $500,000 or more per year begins. It doesn't mean that in the first year it will be $500,000, But it has the opportunity to grow, as this is a "land and expand" type of strategy where we initially implement a couple of AI models and bring them into production. So, we can then start expanding the offering to those customers. But that's a really important one. And we've been moving forward nicely with that target. And then, aiming for cash flow positivity by the end of next year. So, we are on track to achieve that as well. But yeah, there's a lot we need to do. We need to close deals. We need to keep costs under control. And currently, it feels okay. So, we are on the right track in doing all of those and delivering on them. Now it's time for Q&A.
I don't know if Matthew wants to join me at the front as well. So if it's a difficult question, Then I will refer to this gentleman here.